The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

Status Completed

Clinical Trial Summary

In Part 1, subjects will be administered thiamine, thiamine with metformin, and thiamine with trimethoprim. Part 2 will expand on Part 1 and subjects will be administered thiamine and thiamine with trimethoprim. The goal is to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine (Vitamin B1).

Clinical Trial Description

Thiamine is an essential vitamin meaning humans must consume thiamine from their diet in order to stay healthy. Low thiamine levels can lead to adverse events. Thiamine is absorbed in the intestine by a transporter protein. This is made by the SLC19A3 gene. The SLC19A3 gene provides instructions for making the thiamine transporter protein, which moves thiamine into cells. Certain drugs, like metformin and trimethoprim, have been shown to interrupt function of the SLC19A3 gene. Metformin is a first-line therapy for patients with Type 2 diabetes and is associated with improvements in diabetic complications. Trimethoprim is an anti-bacterial drug that is often prescribed to treat infections such as urinary tract infections. At different phases of this study, participants will be administered thiamine, thiamine with metformin, and/or thiamine with trimethoprim to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine. The levels of thiamine in the participants' blood and urine will be measured before and after taking thiamine or thiamine in combination with metformin and/or trimethoprim. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03746106
Study type	Interventional
Source	University of California, San Francisco
Contact
Status	Completed
Phase	Phase 4
Start date	January 28, 2019
Completion date	August 10, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03550794` - Thiamine as a Renal Protective Agent in Septic Shock	Phase 2
Completed	`NCT03263442` - High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Completed	`NCT05663164` - Effect of Thiamine on Serum Glucagon And Reactive Oxygen Species (ROS)	N/A
Withdrawn	`NCT03122678` - Thiamine Supplementation in Patients With Septic Shock	Phase 1
Completed	`NCT04641104` - The Thiamine Administration After Cardiac Surgery Trial	Phase 4
Recruiting	`NCT06298344` - The Role of Thiamine After Transcatheter Closure in Children With Left-to-Right Shunt Congenital Heart Disease	Early Phase 1
Completed	`NCT03626337` - Thiamine Responsive Disorders (TRD) Among Infants in Lao PDR
Completed	`NCT05390086` - Further Development and Assessment of Tools to Measure Risk Factors for and Treatment of Thiamine Deficiency Disorders
Recruiting	`NCT05480943` - Prevalence of Thiamine Deficiency in Hospitalized Non-Alcoholic Veterans
Active, not recruiting	`NCT04453761` - Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass	Phase 4
Completed	`NCT03554668` - Systemic Inflammatory Response: Thiamine and Magnesium Status (Sir TaM Study)
Completed	`NCT01524315` - Preoperative Parenteral Thiamine Supplementation in Patients Undergoing Heart Surgery	Phase 4
Completed	`NCT03616288` - Trial of Thiamine Supplementation in Cambodia	N/A
Completed	`NCT02464865` - Thiamin Deficiency in Obese Thai Children	Phase 4
Completed	`NCT03228030` - Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial	Phase 1